| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Thane Wettig
Also a director
Chief Executive Officer and Director
|
61 | Not stated | Not stated | $2,113,842 | |
|
David DeLucia
Chief Financial Officer
|
37 | Not stated | Not stated | $1,110,999 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Oct 1, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
James A. Schoeneck
Board chair
|
68 |
2010
16 years
|
Not stated |
Audit Committee
|
Connect BioPharma | $174,112 | |
|
Thane Wettig
CEO
|
61 | Not stated | Not independent | None stated | None stated | Paid as CEO | |
|
Jeffrey L. Edwards
|
65 |
2015
11 years
|
Not stated |
Audit Committee · Chair
|
Bio-Rad Laboratories, Inc. | $111,612 | |
|
Michael G. Kauffman
|
62 |
2025
1 year
|
Not stated |
Compensation Committee
|
Verastem Oncology | $91,726 | |
|
Andrew E. Singer
Joined Oct 1, 2026
|
- | - | - |
Audit Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...
